Bristol-Myers Squibb's Richard Furlaud is not "departed" from the company as incorrectly reported by "The Pink Sheet" (Sept. 17, T&G-12). Furlaud, formerly the chairman of Squibb, is now president of the combined BMS and holds a board position through 1993. He stepped down from a transition role in charge of the merged drug businesses earlier this summer.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.